Exceptional response to everolimus is reported in patient with bladder cancer ... Oncology Nurse Advisor A patient with advanced bladder cancer experienced a complete response to the drug combination everolimus and pazopanib in a phase 1 clinical trial. Genomic profiling of his tumor revealed two mutations that may have caused this exceptional response. |
